| 000 | 01503 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250515034301.0 | ||
| 264 | 0 | _c20061208 | |
| 008 | 200612s 0 0 eng d | ||
| 022 | _a1742-7835 | ||
| 024 | 7 |
_a10.1111/j.1742-7843.2006.pto_437.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJaakkola, Tiina | |
| 245 | 0 | 0 |
_aPioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. _h[electronic resource] |
| 260 |
_bBasic & clinical pharmacology & toxicology _cJul 2006 |
||
| 300 |
_a44-51 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C8 |
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xmetabolism |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xpharmacokinetics |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 |
_aMicrosomes, Liver _xdrug effects |
| 650 | 0 | 4 |
_aNADP _xmetabolism |
| 650 | 0 | 4 | _aPioglitazone |
| 650 | 0 | 4 |
_aThiazolidinediones _xpharmacokinetics |
| 700 | 1 | _aLaitila, Jouko | |
| 700 | 1 | _aNeuvonen, Pertti J | |
| 700 | 1 | _aBackman, Janne T | |
| 773 | 0 |
_tBasic & clinical pharmacology & toxicology _gvol. 99 _gno. 1 _gp. 44-51 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1742-7843.2006.pto_437.x _zAvailable from publisher's website |
| 999 |
_c16456618 _d16456618 |
||